a year ago

EpilepsyGTx Secures $10M in Seed Funding for Gene Therapy Research

  • EpilepsyGTx, a biotech company focused on gene therapies for focal refractory epilepsy, raised $10M in Seed funding to complete preclinical studies and prepare Phase 1/2a clinical study.

      • ProblemHealthcare

      "Patients suffering from focal refractory epilepsy, where standard treatments are ineffective"

      Solution

      "Deliver a single dose of gene therapy directly to the seizure focus through a minimally invasive surgical procedure, without requiring permanent destruction of cerebral tissue"

      Covered on